)
Chrysos (C79) investor relations material
Chrysos H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Achieved 49% year-over-year revenue growth to $43.3 million and 152% EBITDA growth to $14.4 million, with EBITDA margin expanding to 33% from 20%, driven by global PhotonAssay adoption and strong gold market conditions.
Deployed 43 PhotonAssay units globally, with 14 new lease agreements signed and a total of 72 contracted units, reflecting robust market adoption and a strong sales pipeline.
Record sample volumes approaching 1 million per month, with PhotonAssay endorsed by all four major laboratory partners and adopted by 70% of the top 20 gold miners.
Net profit after tax reached $0.732 million, marking a transition to statutory profitability.
International revenue accounted for over 50% of total revenue, with expansion in Africa, North America, Australia, and Europe.
Financial highlights
Revenue for the half was $43.3 million, up 49% year-on-year; EBITDA reached $14.4 million, up 152%, with margin expanding to 33% from 20%.
Operating cash flow was $8.6 million, reflecting higher EBITDA and improved cash conversion.
Additional Assay Charges (AAC) rose to 27% of total revenue, up from 11% in the prior year, with AAC revenue at $11.7 million, up 261%.
Gross profit margins for PhotonAssay remained strong at approximately 76%.
Minimum Monthly Assay Payments (MMAP) increased 22% to $31.5 million year-over-year.
Outlook and guidance
FY26 guidance reaffirmed: revenue between $80–90 million and EBITDA between $20–27 million, with current trading tracking toward the upper end of both ranges.
Strong funding and liquidity position supports continued growth and capital expenditure for further PhotonAssay deployments.
Ongoing international expansion and new sales resources in Latin America to accelerate regional engagement.
Industry cycle remains supportive, utilization elevated, and AAC performance strong into the second half.
Conservative guidance maintained due to FX volatility, particularly AUD/USD swings affecting USD-denominated income.
- Q4 revenue up 58% YoY to $13.5m; FY25 guidance: $60–70m revenue, $9–19m EBITDA.C79
Q4 20243 Feb 2026 - Revenue up 69%, EBITDA up 156%, 29 units deployed, and strong FY25 growth outlook.C79
H2 202423 Jan 2026 - Q1 FY25 revenue up 54% YoY to $13.7m, with record sample volumes and global expansion.C79
Q1 202519 Jan 2026 - Q2 FY25 revenue up 53% YoY to $15.3m, with record sample volumes and global expansion.C79
Q2 202510 Jan 2026 - Revenue up 54% and EBITDA up 150% as global PhotonAssay adoption accelerates.C79
H1 202523 Dec 2025 - Record PhotonAssay volumes, global expansion, and next-gen tech drive strong growth and outlook.C79
AGM 2025 Presentation24 Nov 2025 - 46% revenue and 80% EBITDA growth, global expansion, and strong FY26 outlook.C79
H2 202523 Nov 2025 - 46% revenue and 80% EBITDA growth, global expansion, and strong FY26 outlook.C79
Q4 202520 Oct 2025 - PhotonAssay delivers rapid, accurate gold analysis, fueling global growth and sustainability gains.C79
Macquarie Australia Conference Presentation2 Jul 2025
Next Chrysos earnings date
Next Chrysos earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)